ReviewClinical chemistry2010
Protein microarrays for personalized medicine.
Review in Clinical chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Strategies for Monitoring Serum Protein Degradation With an Antibody Array-Based Technology.Journal of clinical laboratory analysis · 2026Article
- Multi-omics to study chronic respiratory diseases and viral infections.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- Inflammatory Mechanisms of Dysmenorrhea: Novel Insights From Menstrual Effluent in an Adolescent Cohort.BJOG : an international journal of obstetrics and gynaecology · 2025Article
- Proteomics appending a complementary dimension to precision oncotherapy.Computational and structural biotechnology journal · 2024Review
- The Progress in Bioprinting and Its Potential Impact on Health-Related Quality of Life.Bioengineering (Basel, Switzerland) · 2023Review
- Liquid Biopsies, Novel Approaches and Future Directions.Cancers · 2023Review
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques.Diagnostics (Basel, Switzerland) · 2022Review
- Proteomics technologies for cancer liquid biopsies.Molecular cancer · 2022Review
- Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.Frontiers in immunology · 2022Review
- Evaluation of the Molecular Mechanisms of Sepsis Using Proteomics.Frontiers in immunology · 2021Review
- COVID-19 diagnostic testing: Technology perspective.Clinical and translational medicine · 2020Article
- Omics for the future in asthma.Seminars in immunopathology · 2020Review
- Efficacy of Integrating a Novel 16-Gene Biomarker Panel and Intelligence Classifiers for Differential Diagnosis of Rheumatoid Arthritis and Osteoarthritis.Journal of clinical medicine · 2019Article
- In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine.Theranostics · 2019Article
- Photoactivatable Reaction for Covalent Nanoscale Patterning of Multiple Proteins.ACS applied materials & interfaces · 2018Article
- Key Enabling Technologies for Point-of-Care Diagnostics.Sensors (Basel, Switzerland) · 2018Review
- New Insights into the Tumor Microenvironment Utilizing Protein Array Technology.International journal of molecular sciences · 2018Review
- Using omics approaches to understand pulmonary diseases.Respiratory research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last 10 years, DNA microarrays have achieved a robust analytical performance, enabling their use for analyzing the whole transcriptome or for screening thousands of single-nucleotide polymorphisms in a single experiment. DNA microarrays allow scientists to correlate gene expression signatures with disease progression, to screen for disease-specific mutations, and to treat patients according to their individual genetic profiles; however, the real key is proteins and their manifold functions. It is necessary to achieve a greater understanding of not only protein function and abundance but also their role in the development of diseases. Protein concentrations have been shown to reflect the physiological and pathologic state of an organ, tissue, or cells far more directly than DNA, and proteins can be profiled effectively with protein microarrays, which require only a small amount of sample material. CONTENT: Protein microarrays have become well-established tools in basic and applied research, and the first products have already entered the in vitro diagnostics market. This review focuses on protein microarray applications for biomarker discovery and validation, disease diagnosis, and use within the area of personalized medicine. SUMMARY: Protein microarrays have proved to be reliable research tools in screening for a multitude of parameters with only a minimal quantity of sample and have enormous potential in applications for diagnostic and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.